01—Abstract
Summary
Summary of the 10-K filed February 7, 2022. Cited figures are marked; the original filing is the authoritative source.
Regeneron's FY2021 10-K shows a dramatic earnings year driven by COVID-19 antibody REGEN-COV, with total revenues of $16.07 billiona (up 89% from $8.50 billion in 2020) and net income of $8.08 billion ($71.97 diluted EPS vs. $30.52).
Excluding REGEN-COV, the franchise remains anchored by EYLEA (U.S. net sales $5.79 billionb, up 17%) and Dupixent (collaboration profits with Sanofi, with global Dupixent, Praluent, and Kevzara net sales of $6.54 billion). The filing emphasizes that REGEN-COV's U.S. EUA was revised in January 2022 to exclude all U.S. jurisdictions because of Omicron resistance, and the company took a $231.7 million inventory write-down, so the COVID windfall should be viewed as non-recurring and highly uncertain. The core commercial risk is concentration: EYLEA represented 36% of 2021 revenues (58% in 2020), and biosimilar competition is expected to begin with the U.S. regulatory exclusivity period ending November 2023.
Dupixent's growth is a key offset, and the pipeline includes several late-stage programs (aflibercept 8 mg, odronextamab, pozelimab, and additional Dupixent indications) with 2022 milestones. Balance-sheet strength is significant, with $12.5 billionc in cash and marketable securities against $2.0 billion of senior notes and a $720 million Tarrytown lease that was being extended, alongside $6.0 billion of accounts receivable (about half from the U.S. government and two distributors) and a $3.0 billion buyback authorization.
Investors should also weigh legal and regulatory exposure: a DOJ False Claims Act and Anti-Kickback civil case over patient assistance, a new DOJ CID on EYLEA pricing and rebates, multiple RICO suits from insurers, and ongoing Praluent and EYLEA patent litigation. Pricing pressure from Medicare drug-price reform proposals is an additional risk for EYLEA.
02—Key points
Key Highlights
- Record 2021 revenue of $16.07B (+89% YoY) and net income of $8.08B ($71.97 diluted EPS), but heavily boosted by REGEN-COV sales to the U.S. government (~$5.83B U.S. net product sales).
- REGEN-COV lost its U.S. EUA scope in January 2022 (Omicron resistance), leaving no authorized U.S. jurisdictions; the company wrote down $231.7M of REGEN-COV inventory in Q4 2021.
- EYLEA is the dominant franchise: U.S. net sales of $5.79B (+17%) and 36% of total 2021 revenue, creating high concentration risk ahead of biosimilar entry (regulatory exclusivity expires November 2023).
- Dupixent (via Sanofi collaboration) drove Sanofi collaboration revenue to $1.90B (+60%), with global Dupixent net sales of about $6.2B and Regeneron's collaboration profit share rising to 21% of antibody sales.
- Strong liquidity: $12.5B in cash and marketable securities versus $2.0B in long-term senior notes; $2.85B remaining under the $3.0B buyback authorization.
- Large receivables build: accounts receivable rose $1.93B to $6.04B, with three customers (including the U.S. government at 29%) comprising 91% of trade receivables.
- Significant legal exposure, including a DOJ civil False Claims/Anti-Kickback action, a June 2021 DOJ CID on EYLEA kickbacks and pricing, RICO suits from UnitedHealthcare, Humana, and BCBS, and Praluent patent litigation with Amgen.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2021filed February 7, 2022Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $16.07B$8.50B | +89.1% |
| R&D Expenses | $2.86B$2.65B | +8.1% |
| SG&A Expenses | $1.82B$1.35B | +35.6% |
| Operating Expenses | $7.12B$4.92B | +44.8% |
| Operating Income | $8.95B$3.58B | +150.1% |
| Interest Expense | $57.30M$56.90M | +0.7% |
| Net Income | $8.08B$3.51B | +129.9% |
| EPS (Basic) | $76.40$32.65 | +134.0% |
| EPS (Diluted) | $71.97$30.52 | +135.8% |
| Shares Outstanding (Basic) | 105.70M107.60M | −1.8% |
| Shares Outstanding (Diluted) | 112.20M115.10M | −2.5% |
05—Questions
Frequently Asked Questions
How much of Regeneron's 2021 revenue was a one-time COVID-19 benefit?
REGEN-COV generated $7.57B of total net product sales in 2021, including $5.83B in U.S. net product sales recorded from U.S. government agreements and $1.75B of ex-U.S. sales recorded by Roche, with the company sharing gross profits. U.S. government deliveries were completed by December 31, 2021, so 2022 sales depend on new authorizations, which the company describes as highly uncertain.
What is the biggest risk to Regeneron's revenue beyond COVID-19?
EYLEA concentration is the key risk: it made up 36% of 2021 revenue. Biosimilar and branded competition (including Vabysmo, Byooviz, and Lucentis biosimilars) is increasing, and loss of exclusivity would materially reduce sales. Pending patent challenges in the USPTO and EPO, plus Medicare drug-price reform proposals, add further uncertainty.
How strong is Regeneron's balance sheet and capital allocation?
Regeneron ended 2021 with $12.5B in cash and marketable securities and $2.0B of senior unsecured notes, plus an undrawn $750M revolver. Operating cash flow was $7.08B. The company repurchased $1.66B of stock in 2021 and had $2.85B left under its November 2021 authorization. Capital expenditures are guided to $650M-$730M for 2022 for manufacturing and Tarrytown expansion.
What are the main pipeline catalysts for 2022?
Key 2022 milestones include an FDA decision on Dupixent for pediatric atopic dermatitis (mid-2022), an sBLA for EYLEA every-16-week dosing in NPDR (first half 2022), detailed aflibercept 8 mg Phase 2 wet AMD results (Q1 2022), an FDA decision on Libtayo first-line NSCLC combination (target September 19, 2022), and Phase 3 starts for odronextamab and fianlimab. Timelines may slip due to COVID-19 effects.
What legal issues could materially affect Regeneron?
The DOJ civil complaint (filed June 2020) alleges Anti-Kickback Statute and False Claims Act violations related to patient assistance; additional DOJ CIDs cover physician remuneration and EYLEA kickbacks and average sales price reporting. Insurer RICO lawsuits seek damages tied to the same conduct. The filing does not accrue a material liability, and outcomes are uncertain, though a loss could be significant.
06—Continue